Manifaxine

Manifaxine is a dopamine and norepinephrine reuptake inhibitor that was under development for the treatment of depression and fatigue, but was discontinued. It was developed by GlaxoSmithKline.

Pharmacology

Manifaxine acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). It inhibits the reuptake of dopamine and norepinephrine, thereby increasing their concentrations in the brain. This results in increased neurotransmission, which can help to alleviate symptoms of depression and fatigue.

Development and Discontinuation

Manifaxine was developed by GlaxoSmithKline for the treatment of depression and fatigue. However, the development of the drug was discontinued for unknown reasons. It is not currently available for medical use.

See Also

• Dopamine reuptake inhibitor
• Norepinephrine reuptake inhibitor
• GlaxoSmithKline

References

Manifaxine Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski